抄録
The administration of extracellular, hemoglobin-based oxygen carriers often elicits an acute increase in blood pressure by vasoconstriction. This side effect is now recognized to be due to the depletion of nitric oxide (endothelial-derived relaxing factor) by the extravasuated hemoglobins. We have recently found that the administration of a recombinant human serum albumin (rHSA)-based oxygen carrier involving synthetic tetraphenyporphinatoiron(II) derivative (FeP) (rHSA-FeP) does not induce such hypertensive action, because of its low permeability through the vascular endothelium. The heart rate responses after the rHSA-FeP injection were also negligibly small. Visualization of the intestinal microcirculatory changes clearly revealed the widths of the venule and arteriole to be fairly constant. The entirely synthetic rHSA-FeP becomes a promising material as a new type of red blood cell substitute.
本文言語 | English |
---|---|
ページ(範囲) | 257-261 |
ページ数 | 5 |
ジャーナル | Journal of Biomedical Materials Research - Part A |
巻 | 64 |
号 | 2 |
DOI | |
出版ステータス | Published - 2003 2月 1 |
ASJC Scopus subject areas
- セラミックおよび複合材料
- 生体材料
- 生体医工学
- 金属および合金